Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maruishi Pharmaceutical Co. Ltd.

www.maruishi-pharm.co.jp

Latest From Maruishi Pharmaceutical Co. Ltd.

Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?

Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.

Respiratory Clinical Trials

Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva

A Vifor Fresenius joint venture will market Korsuva for CKD-associated pruritis to Fresenius dialysis centers in Europe, and also will do a co-promotion with Cara in the US that may provide a significant head start for the drug.

Deals Commercial

Faron’s Traumakine Flops In Phase III

Faron Pharmaceuticals’ stock has plummeted more than 80% on the news its lead drug failed in a Phase III trial – the company will now shift its focus to an investigational cancer therapy, but this is yet to enter the clinic.

Business Strategies Research and Development Strategies

Faron CEO Markku Jalkanen Outlines Commercial Ambitions

The US FDA approves IND application of Faron’s lead Traumakine program for acute respiratory distress syndrome as company prepares for pivotal Phase III data readout this spring. The CEO outlines company’s Traumakine commercialization plans and provides update on its Clevegen ambitions.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Maruishi Pharmaceutical Co. Ltd.
  • Senior Management
  • Keiichi Inoue, Pres.
  • Contact Info
  • Maruishi Pharmaceutical Co. Ltd.
    Phone: (81) (06) 6964-3100
    2-4-2 Imazu-Naka
    Tsurumi-ku
    Osaka, 538-0042
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register